within Pharmacolibrary.Drugs.ATC.M;

model M01AX25
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 0.13,
    Cl             = 3.3333333333333333e-06,
    adminDuration  = 600,
    adminMass      = 1200 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.018,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.00035,
    Tlag           = 600
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>M01AX25</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Chondroitin sulfate is a sulfated glycosaminoglycan used as a dietary supplement, commonly in osteoarthritis for its potential to reduce symptoms and improve joint function. It is not approved as a prescription drug in the USA or EU but is used over the counter in many countries. Its clinical efficacy as a drug is debated.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetics in healthy adult volunteers after oral administration; published sources do not clearly report population pharmacokinetic models.</p><h4>References</h4><ol><li><p>Volpi, N, et al., &amp; Miraglia, N (2019). Oral Bioavailability and Pharmacokinetics of Nonanimal Chondroitin Sulfate and Its Constituents in Healthy Male Volunteers. <i>Clinical pharmacology in drug development</i> 8(3) 336–345. DOI:<a href=\"https://doi.org/10.1002/cpdd.587\">10.1002/cpdd.587</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/30040242/\">https://pubmed.ncbi.nlm.nih.gov/30040242</a></p></li><li><p>Ewald, CY (2021). Drug Screening Implicates Chondroitin Sulfate as a Potential Longevity Pill. <i>Frontiers in aging</i> 2 741843–None. DOI:<a href=\"https://doi.org/10.3389/fragi.2021.741843\">10.3389/fragi.2021.741843</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/35821992/\">https://pubmed.ncbi.nlm.nih.gov/35821992</a></p></li><li><p>Yan, L, et al., &amp; Chen, S (2021). Oral Administration of Fucosylated Chondroitin Sulfate Oligomers in Gastro-Resistant Microcapsules Exhibits a Safe Antithrombotic Activity. <i>Thrombosis and haemostasis</i> 121(1) 15–26. DOI:<a href=\"https://doi.org/10.1055/s-0040-1714738\">10.1055/s-0040-1714738</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/32862408/\">https://pubmed.ncbi.nlm.nih.gov/32862408</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end M01AX25;
